About Us

Overview

Millendo Therapeutics is focused on developing novel treatments for endocrine diseases caused by hormone dysregulation. Our mission is to build a leading endocrine company that creates distinct and transformative treatments for a wide range of diseases where there is a significant unmet medical need. We are currently advancing our lead product candidate, ATR-101, for the treatment of three different orphan adrenal diseases: Classic Congenital Adrenal Hyperplasia (CAH), Endogenous Cushing’s Syndrome (CS), and Adrenocortical Carcinoma (ACC).